冻干重组人脑利钠肽在老年急性心力衰竭患者 应用的安全性评价-内科学专业论文.docxVIP

目 录 中文摘要···········································································································1 英文摘要···········································································································6 英文缩写·········································································································10 研究论文 冻干重组人脑利钠肽在老年急性心力衰竭患者应用的安全性 评价 前言·········································································································12 材料与方法·····························································································14 结果·········································································································17 附图·········································································································21 附表·········································································································23 讨论·········································································································26 结论·········································································································28 参考文献·································································································29 综述 钠尿肽系统在心力衰竭???理生理学中的作用·······························31 致谢·················································································································38 个人简历········································································································39  冻干重组人脑利钠肽在老年急性心力衰竭患者 应用的安全性评价 摘 要 目的：本研究旨在评价老年急性心力衰竭（acutely heart failure, AHF） 患者静脉应用冻干重组人脑利钠肽（recombinant human brain natriuretic peptide, rh-BNP）的安全性。 方法：本研究为前瞻、随机对照研究。入选 2014 年 7 月至 2015 年 7 月就诊于河北医科大学第二医院心内五科病房的老年急性心力衰竭连续 病 例 ， 并 将 入 选 患 者 按 照 随 机 数 字 表 法 分 为 冻 干 重 组 人 脑 利 钠 肽 组 （rh-BNP 组）和对照组（CON 组）。入选标准：年龄≥75 岁的老年患者， NYHA 心功能为 III 级～Ⅳ级的 AHF 患者，左心室射血分数（left ventricular ejection fraction, LVEF）45％。排除标准：心原性休克、血容量不足或任 何其他临床情况禁忌给予血管扩张剂者；同时伴随有其他严重疾病，例如 肥厚型或限制型心肌病